WHAT AND WHERE IS HEAVEN?

Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
https://www.amazon.com/dp/B086J9VKZD
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

VISIONS AND HALLUCINATIONS

This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
https://www.amazon.com/dp/B088GP64MW 
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


Observations placeholder

Pearls & Oy-sters: Bismuth neurotoxicity from use of topical bismuth dressing for burns

Identifier

029513

Type of Spiritual Experience

Hallucination

Number of hallucinations: 1

Background

A description of the experience

Pearls & Oy-sters: Bismuth neurotoxicity from use of topical bismuth dressing for burns Vasu Saini, MD, Renata Chalfin, MD, Janice Leon, MD, and Jason Margolesky, MDNeurology®2019;92:680-681.
Neurology | Volume 92, Number 14 | April 2, 201

doi:10.1212/WNL.0000000000007236CorrespondenceDr. Margoleskyjhmargolesky@med.miami.eduPearlsc

A common inpatient neurology consult is for the evaluation of toxic-metabolic encephalopathy, for which the differential diagnosis is broad

Bismuth encephalopathy is a rare etiology; toxicity from topical bismuth-containing compounds even rarer.  Bismuth encephalopathy can manifest with confusion (which can progress to coma),myoclonus, gait/appendicular ataxia, dysarthria, hallucinations, paresthesia, and seizures.  CT brain may show hyperdensities in the basal ganglia, cerebellum, and cerebral cortex due to accumulation of bismuth within these sites, which may resolve with resolution of toxicity

Oy-sters.  When reviewing medications and metabolic derangements in the investigation of toxic-metabolic encephalopathy, bismuth exposure may be under-recognized and missed.  Bismuth toxicity can mimic other encephalopathies associated with myoclonus such as Creutzfeldt-Jakob disease (CJD) and steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT).  Serum and urine bismuth levels can be measured, but if toxicity is expected, bismuth exposure must be immediately discontinued.  Missing this diagnosis can lead to easily avoidable morbidity and mortality

Bismuth-containing ointment has been used for the dressing of wounds since World War I.

1 Apopular option for burns and skin grafts, bismuth iodoform paraffin paste (BIPP) is a sterile gauze impregnated with 2 active ingredients: bismuth subnitrate and iodoform.

2  Because it does not get infected with chronic use in deep wounds, it is often left in situ for weeks.2BIPP is also used in maxillofacial and neurologic surgeries, where case reports have noted a rare adverse effect of toxic encephalopathy.

3  However, the literature on toxic encephalopathy caused byBIPP used for burn wounds is sparse.

Case report

A 53-year-old man with a history of uncontrolled diabetes and severe polyneuropathy was admitted to the trauma service for treatment of 3rd to 4th degree burns of the legs. He sustained the burns 2 weeks prior to presentation from placing his legs in hot water for a prolonged period, and he did not seek medical attention immediately due to lack of pain. On presentation,he had foul-smelling purulent drainage on both feet to the ankles, which required surgical debridement. The patient’s wounds were dressed using BIPP, about 100 g twice daily.

A month into his hospitalization, we were consulted because the patient was confused, agitated, and aimlessly wandering. On examination, he had impaired attention. He was oriented to only self and place, and able to follow only simple commands. He had occasional myoclonus. No other deficits were noted on examination. Renal, liver, and thyroid functions, as well as ammonia level,  were normal. Evaluation for active infection, including blood and urine cultures, was also negative. MRI of the brain without contrast revealed an incidental chronic punctate ischemic infarct of the left lateral pons, which a complete stroke in-vestigation found was likely secondary to chronic small vessel disease from uncontrolled diabetes.

An EEG demonstrated slow background activity in delta/theta range with absent posterior dominant rhythm suggestive of moderate–severe encephalopathy; there were no seizures or electrographic correlate with the myoclonic jerks noted. At the time of consultation, we requested blood and urine bismuth levels and recommended his BIPP be discontinued, after which his mental status gradually improved. The urine bismuth level eventually returned significantly elevated at 213.7μg/g cre-atinine (normal range <7μg/g creatinine). The blood bis-muth level was unable to be measured at our institution.  Discussion

Acute bismuth toxicity is more likely to cause renal failure, whereas chronic toxicity is more systemic and more likely to cause neurologic manifestations.4,5  Our patient developed symptoms after 1 month of daily exposure. Signs of bismuth encephalopathy include confusion (which can progress to coma), myoclonus, gait/appendicular ataxia, dysarthria, hal-lucinations, paresthesia, and seizures.6  Bismuth toxicity has also been associated with bilateral, diffuse basal ganglia, cer-ebellar, and cerebral cortical hyperdensities on CT, though not all patients reported have had these findings, as in our case.7,8  CT abnormalities may resolve with resolution of bis-muth toxicity.7 Blood and urine bismuth levels can be mea-sured,9  but do not seem to differential acute from chronic exposure. In patients with bismuth encephalopathy, blood levels range from 50 to 1,600μg/L and urine levels range from150 to 1,250μg/L.  9Blood and urine levels correlate well.10 

The mainstay of treatment is discontinuation of bismuth-containing compounds and supportive care.9 Topical bismuth can be absorbed systemically and cause toxicity if used over injured skin.1,11 Even small amounts used over time appear to accumulate in the kidney for months.12  Bismuth toxic encephalopathy is a rare adverse effect of bismuth-containing oral formulations, and if not recognized early, can be fatal.13  The most common adverse effect of oral formulation is a darkening of stool.6  Our case highlights the incidence of bismuth encephalopathy associated with topical BIPP used for burn wounds. Typically, it is characterized by confusion, ataxia, and myoclonus, but atypical presentations consisting of solely behavioral changes or suicidal ideation have been described.3  In our case, frequent myoclonic jerks in the acute phase, without EEG correlate, were present.

Krugeret al.11 suggested that bismuth can cross the blood–brain barrier and bind to enzymes involved in oxidative metabolism, leading to reduced oxygen consumption, increased lactate production, and thus reduced cerebral bloodflow.  Of note, several cases of altered mental status have been de-scribed in association with iodoform gauze, usually correlating with high serum iodine levels.14  BIPP contains both bismuth and iodine, thus our patient was exposed to both potentially toxic compounds. Though we did not check iodine levels in our patient, the normal thyroid function and significantly el-evated urine bismuth level is more consistent with bismuth toxicity.  Bismuth toxic encephalopathy should be part of the differ-ential for any burn patients receiving BIPP for wound dress-ing, as early recognition of the syndrome is important to prevent long-term cognitive sequelae or even death.

 

The source of the experience

PubMed

Concepts, symbols and science items

Concepts

Symbols

Science Items

Activities and commonsteps

Commonsteps

References